News
Hypofractionated radiotherapy: New normal for lung cancer?
- Author:
- Sara Freeman
Almost 20% of lung cancer patients in a U.K. study had their radiotherapy dose or fractionation schedule changed during the first wave of the...
News
Camrelizumab ‘another brick in the wall’ against squamous NSCLC
- Author:
- Sara Freeman
Adding camrelizumab to chemotherapy improved survival in patients with squamous non–small cell lung cancer.
News
Can benefits of SBRT outweigh risks in ultra-central lung tumors?
- Author:
- Sara Freeman
Stereotactic body radiotherapy for ultra-central lung tumors offers good disease control and survival but carries a risk of lung hemorrhage.
News
KRYSTAL-1: Clear activity of adagrasib in KRAS-mutated NSCLC
- Author:
- Sara Freeman
Phase 1/2 results with adagrasib confirm KRAS G12C as a druggable target in non–small cell lung cancer.
News

RA expert updates latest pathologic findings from Accelerating Medicines Partnership
- Author:
- Sara Freeman
Researchers have used single-cell analytic techniques to reveal pathologic RA synovial tissue differences in stromal and immune cells between...
News
No benefit seen with everolimus in early breast cancer
- Author:
- Sara Freeman
There were no improvements in survival when everolimus was added to hormone therapy.
News

OA risk-reduction program targets injured knees
- Author:
- Sara Freeman
The Stop Osteoarthritis program is currently testing the feasibility of a three-part intervention to help prevent posttraumatic knee OA.
News

Pandemic puts patients with psoriatic disease off seeking medical help
- Author:
- Sara Freeman
Both the physical and mental health of people with psoriasis and psoriatic arthritis has been affected by the ongoing COVID-19 pandemic.
News

Rheumatologic disease activity an important influencer of COVID-19 death risk
- Author:
- Sara Freeman
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from...
News
Entinostat doesn’t overcome endocrine resistance in advanced breast cancer
- Author:
- Sara Freeman
Phase 3 results do not support use of entinostat in advanced breast cancer.
News
Study: Doctors underreport side effects of breast irradiation
- Author:
- Sara Freeman
A large study shows a mismatch between patient and physician reports of toxicity.
News

No edge for anastrozole over tamoxifen in DCIS
- Author:
- Sara Freeman
Breast cancer recurrence rates were similar at almost 12 years of follow-up.
News

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients
- Author:
- Sara Freeman
PRIME-2 study results show no drop in overall survival from omitting postop radiotherapy in older women with HR+, low-risk, early-stage breast...
News

An all-oral option for advanced HR+, HER2– breast cancer?
- Author:
- Sara Freeman
Adding the oral taxane tesetaxel to capecitabine improved progression-free survival.
News
PENELOPE-B: Palbociclib disappoints in HR+, HER2– breast cancer
- Author:
- Sara Freeman
Adding palbociclib to endocrine therapy after neoadjuvant chemotherapy did not benefit patients with HR+, HER2-...